FlandersBio on Twitter

Follow us on Twitter

Archive for May 2010 - News

Archive for May 2010 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

OncoMethylome shareholders pass all resolutions at AGM and appoint three new independent directors

31.05.2010

OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, today announced that its Annual General Shareholders' Meeting (AGM) held on 28 May, 2010, approved the appointment of Ms. Hilde Windels, Mr. Edward L. Erickson, and Mr. Mark Myslinski to the Board of Directors, as well as all other agenda items of the AGM. The appointment of the new directors is effective immediately for a period until the 2013 AGM. read more

OncoMethylome Sciences receives ISO 9001:2008 certification

27.05.2010

OncoMethylome Sciences (Euronext Brussels: ONCOB; Euronext Amsterdam: ONCOA), a leading molecular diagnostics company, announced today that its Belgium based clinical diagnostics service laboratory has received the important ISO 9001:2008 certification from Lloyds Register Quality Assurance Ltd. read more

Slaapziekte bestrijden met gloeiende testikels - gentechnologie legt onverwachte schuilplaats van de parasiet bloot

27.05.2010

Onderzoekers van het Instituut voor Tropische Geneeskunde ontdekten bij toeval dat de slaapziekteparasiet niet alleen zo lastig te bestrijden is omdat hij zich in de hersenen verschuilt - wat we al langer wisten - maar ook in testikels. De ontdekking kwam er nadat de vorsers er in geslaagd waren om een lichtgevende versie van de slaapziekteparasiet te kweken. read more

Nanobody® lead candidate selected by Boehringer Ingelheim for development in Alzheimer's Disease

25.05.2010

Ablynx [Euronext Brussels: ABLX] today announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease. This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a €2 million milestone payment to Ablynx. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print